Manufacturing of CAR-T Cells: The Assembly Line

CAR-T cell manufacturing: Major process parameters and next-generation strategies

“…CAR construct design and strategies by which CAR-T cells can be engineered to promote fitness, persistence, and antitumor efficacy have been reviewed in detail in several recent articles ( Gao and Chen, 2022 ; Hamieh et al, 2023 ; Hou et al, 2021 ; Labanieh and Mackall, 2023 ). Here, we focus our attention on autologous CAR-T cell manufacturing, which plays a critical role in the clinical impact of CAR-T cell therapy by influencing the phenotype and function of the CAR-T cell products ( Ceppi et al, 2022 ; Wang and Rivière, 2022 ). Although many of the aspects discussed in this review also apply to the manufacturing of allogeneic CAR-T cells, additional considerations exist for the engineering of donor T cells or the differentiation of stem cells into T-cell products, and discussions on these topics can be found in several excellent articles ( Depil et al, 2020 ; Jing et al, 2022 ; Seet et al, 2017 ; Themeli et al, 2013 ; Ueda et al, 2023 ; van der Stegen et al, 2022 ).…”

Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress

“…Clinical trials have provided compelling evidence of its potential in the context of both adult and pediatric populations, demonstrating the effectiveness of advanced immunotherapy in combatting bone cancer [ 23 , 35 ]. The impact of this therapy has been further underscored by the approval of three notable T cell-based therapeutics—Kymriah, Yescarta, and Breyanzi—by the US FDA [ 36 , 37 , 38 ]. However, though there has been considerable success in hematologic malignancy treatment, including B cell leukemia and lymphoma treatment, adoptive T cell therapy faces inherent challenges that limit its efficacy in the treatment of many solid tumors including OS [ 39 ].…”